Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double-spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”. Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice:).

1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:
   John G. Delinassios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2011 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
22th ANNUAL MEETING OF THE
ITALIAN SOCIETY OF URO-ONCOLOGY (SIUrO)

Savoia Hotels, Via del Pilastro, 2
Bologna, Italy

Deadline for abstract submission: February 3, 2012

Chair
Giuseppe Martorana

Advisory Committee
Alessandro Bertaccini
Eugenio Brunocilla
Marco Garofalo
Fabio Manferrari
Riccardo Schiavina

Organizing Secretariat
Emilia Viaggi Congressi & Meeting S.r.l.
Via Porrettana, 76
40033 Casalecchio di Reno (BO)
Tel.: +39 051 6194911
Fax: +39 051 6194900
e-mail: evcongressi@emiliaviaggi.it
web: www.emiliaviaggi.it

Scientific Secretariat
Società Italiana di Urologia Oncologica (SIUrO)
c/o Clinica Urologica, Alma Mater Studiorum
Università di Bologna
Policlinico S. Orsola Malpighi
Padiglione Palagi, via P. Palagi,
9 – 40138 Bologna
Tel.: +39 051 6362421, 051 302082
Fax: +39 051 308037
e-mail: congresso@siuro.it
web: www.siuro.it

Italian Society of Uro-Oncology (SIUrO)
President: Giuseppe Martorana,
Bologna, Italy
General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal’s scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the International Institute of Anticancer Research and is available online with Stanford University HighWire Press: For more information please visit our websites www.iiar-anticancer.org and www.iiarjournals.org.

Editorial Office
International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece, Tel: +30 22950 52945, Fax: +30 22950 53389
e-mail: journals@iiar-anticancer.org (Editorial Office); IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

Free specimen copies of CGP are available on request.
Salvage Chemotherapy for Ovarian Carcinoma Recurring During or After Consolidation Chemotherapy with Paclitaxel. Y. MIYOSHI, Y. UEDA, A. MORIMOTO, T. YOKOYAMA, S. MATSUZAKI, E. KOBAYASHI, KIMURA TOSHIHIRO, K. YOSHINO, M. FUJITA, T. ENOMOTO, KIMURA TADASHI (Suita, Osaka, Japan) .......................................................... 4613

Clinical Significance of \textit{BRAF} Gene Mutations in Patients with Non-small Cell Lung Cancer. M. KOBAYASHI, M. SONOBE, T. TAKAHASHI, A. YOSHIZAWA, M. ISHIKAWA, R. KIKUCHI, K. OKUBO, C.-L. HUANG, H. DATE (Kyoto, Japan) ........................................................ 4619

Weekly Paclitaxel in Combination with Doxifluridine for Peritoneally Disseminated Gastric Cancer with Malignant Ascites. I. TAKEYOSHI, F. MAKITA, S. IWAZAKI, H. ISHIKAWA, S. KAKINUMA, Y. SATO, T. OHYA, K. NAKAGAMI, N. TOMIZAWA, M. IZUMI, I. KOBAYASHI, Y. TANAHASHI, J. KOBAYASHI, N. KAMOSHIITA, S. KAWATE, Y. SUNOSE, I. SAKAMOTO, D. YOSHINARI, T. YAMADA, T. OKABE (Maebashi; Shibukawa; Tatebayashi; Takasaki; Gunma; Fujiyoshida, Yamanashi; Usui; Koriyama, Fukushima; Oga, Saitama; Suto, Kumamoto, Japan) .................. 4625


Single-agent Paclitaxel in Advanced Anal Cancer after Failure of Cisplatin and 5-Fluorouracil Chemotherapy. A. ABBAS, E. NEHME, M. FAKIH (Buffalo, NY; Ann Arbor, MI, USA) ............................................................... 4637


Clinical Significance of Hypermethylation Status in NSCLC: Evaluation of a 30-Gene Panel in Patients with Advanced Disease. M. PESEK, M. KOPECKOVA, L. BENESOVA, A. MESZAROSOVA, P. MUKENSNAHL, F. BRUHA, M. MINARIK (Pilsen; Prague, Czech Republic) .................................................. 4647

Growth Factors and Breast Tumors, Comparison of Selected Growth Factors with Traditional Tumor Markers. R. KUCERA, M. CERNA, A. NARSANKA, S. SVOBODA, M. STRAKOVA, J. VRZALOVA, R. FUCHSOVA, I. TRESKOVA, T. KYDLICEK, V. TRESKA, L. PECEN, O. TOPOLCAN, P. PAZDIORA (Pilsen; Prague, Czech Republic) .................................................. 4653

Multi-center Phase II Study of FLOX for Advanced Colorectal Cancer Patients in Japan: SWIFT 3 Study. T. KATO, N. NAGATA, M. FUJI, H. TAKEMOTO, K. KONDO, Y. OKUYAMA, H. TOMINAGA, J. SAKAMOTO, H. MISHIMA (Hyogo; Kitakyushu; Osaka; Sakai; Nagoya; Kyoto; Hiroshima, Japan) ......... 4657

Low Dihydropyrimidine Dehydrogenase Correlates with Prolonged Survival in Patients with Lung Adenocarcinoma Treated with 5-Fluorouracil. Y. SHINTANI, M. INOUE, Y. FUNAKOSHI, A. MATSUMURA, M. OHTA, H. MAEDA, M. OKUMURA (Osaka, Japan) ............................................................... 4665

Index ........................................................................................................................................ 4673

Reviews (pages 4083, 4359, 4369, 4387)
Continuous Administration of EGFR-TKIs Following Radiotherapy after Disease Progression in Bone Lesions for Non-small Cell Lung Cancer. M. INOMATA, T. SHUKUYA, T. TAKAHASHI, A. ONO, Y. NAKAMURA, A. TSUYA, H. KENMOTSU, T. NAITO, H. MURAKAMI, H. HARADA, M. ENDO, N. YAMAMOTO (Shizuoka; Toyama; Tokyo, Japan) .............................................................. 4519


Carbonic Anhydrase IX, Hypoxia-inducible Factor-1α, Ezrin and Glucose Transporter-1 as Predictors of Disease Outcome in Rectal Cancer: Multivariate Cox Survival Models following Data Reduction by Principal Component Analysis of the Clinicopathological Predictors. E.A. KORKEILA, J. SUNDBRÖM, S. PYRÖHÖNEN, K. SYRJÄNEN (Turku, Finland) .............................................................. 4529

Retrospective Study of Patients with Brain Metastases from Melanoma Receiving Concurrent Whole-brain Radiation and Temozolomide. N. DEVITO, M. YU, R. CHEN, E. PAN (Tampa, FL, USA) .............................. 4537


Initial Experience with Hepatic Intraarterial Fotemustine and Interferon Alpha 2b Combination for Treatment of Liver Tumors. F.V. VITALE, P. ROMEO, E.M. DI MAGGIO, A. PARISI, E. MALAPONTE, S. CALI, F. VASTA, V. PANEBIANCO, D. ARCORIA, F. FERRARU (Taormina; Catania, Italy) .............................................................. 4553


Impact of Chemotherapy for Colorectal Cancer on Regulatory T-Cells and Tumor Immunity. K. MAEDA, S. HAZAMA, K. TOKUNO, S. KAN, Y. MAEDA, Y. WATANABE, R. KAMEI, Y. SHINDO, N. MAEDA, K. YOSHIMURA, S. YOSHINO, M. OKA (Yamaguchi, Japan) .............................................................. 4569


Trans-Arterial Chemoembolization of Metastatic Colorectal Carcinoma to the Liver Adopting DC Bead®, Drug-eluting Bead Loaded with Irinotecan: Results of a Phase II Clinical Study. C. ALIBERTI, G. FIORENTINI, P.C. MUZZIO, F. POMERRI, M. TILLI, S. DALLARA, G. BENE (Padova; Pesaro; Ferrara, Italy) .............................................................. 4581

Docetaxel, Nedaplatin, and S-1 (DGS) Chemotherapy for Advanced Esophageal Carcinoma: A Phase I Dose-escalation Study. Y. TANAKA, K. YOSHIDA, S. OSADA, K. YAMAGUCHI, T. TAKAHASHI (Gifu City, Gifu, Japan) .............................................................. 4589

Long-term Survival Following Resection of Brain Metastases from Pancreatic Cancer. J. LEMKE, T.F.E. BARTH, M. JUHEMS, T. KAPAPA, D. HENNE-BRUNS, M. KORNMAAN (Ulm, Germany) .............................................................. 4599

Comparison of Lymphangiogenesis between Primary Colorectal Cancer and Corresponding Liver Metastases. A. SCHOPPMANN, D. TAMANDL, B. HERBERGER, F. LANGLE, P. BIRNER, S. GELEFF, T. GRÜNBERGER, S.F. SCHOPPMANN (Vienna, Austria) .............................................................. 4605

Contents continued on the preceding page
Immunohistochemical Study of VEGF Expression in Oral Squamous Cell Carcinomas: Correlation with the mTOR-HIF-1α Pathway. T. NARUSE, G. KAWASAKI, S. YANAMOTO, A. MIZUNO, M. UMEDA (Nagasaki, Japan) .......................................................... 4429

Oxaliplatin, Irinotecan and Cetuximab in Advanced Gastric Cancer. A Multicenter Phase II Trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT). E. WÖLL, R. GREIL, W. EISTERER, O. BECHTER, M.A. FRIDRIK, B. GRÜNBERGER, A. ZABERNIGG, B. MAYRBAURL, G. RUSS, M. DLASKA, P. OBRIST, J. THALER (Zams; Salzburg; Innsbruck; Linz; Vienna; Kufstein; Wels, Austria) .......................................................... 4439

PCA3 Score vs PSA Free/Total Accuracy in Prostate Cancer Diagnosis at Repeat Saturation Biopsy. P. PEPE, F. ARAGONA (Catania, Italy) ........................................................................................................ 4445

The EMT Status in the Primary Tumor Does Not Predict Postoperative Recurrence or Disease-free Survival in Lung Adenocarcinoma. Y. CHIKAISHI, H. URAMOTO, F. TANAKA (Kitakyushu, Japan) ......................... 4451


Anaplastic Oligodendrogial Tumors Harboring 1p/19q Deletion Can Be Successfully Treated without Radiotherapy. Y. IWADATE, T. MATSUTANI, N. SHINOZAKI, N. SAEKI (Chiba City, Chiba, Japan) .......... 4475

Synchronous Double Tumor of Breast Cancer and Gastrointestinal Stromal Tumor in a Patient with Neurofibromatosis Type 1: Report of a Case. H. TAKEUCHI, S. HIROSHIGE, K. HASHIMOTO, T. KUSUMOTO, Y. YOSHIKAWA, Y. MUTO (Beppu, Japan) .......................................................... 4481

Clinical and Histopathological Profile of Primary or Secondary Osteosarcoma of the Jaws. F. ANGIERO, F. MOLTRASIO, G. CATTORETTI, M.G. VALENTE (Genoa; Milan, Italy) .......................................................... 4485


Evidence for Acute Vascular Toxicity of Cisplatin-based Chemotherapy in Patients with Germ Cell Tumour. K.-P. DIECKMANN, W.J. STRUSS, U. BUDDE (Hamburg, Germany) .......................................................... 4501


Dissection of Unsuspicous Para-aortic Lymph Nodes Does Not Improve Prognosis of Advanced Endometrial Carcinoma with Intra- or Extra-abdominal Metastasis. Y. UEDA, M. OKAZAWA, T. ENOMOTO, T. EGAWA-TAKATA, KIMURA TOSHIHIRO, K. YOSHINO, M. FUJITA, Y. OHTA, S. KAMIURA, KIMURA TADASHI (Osaka, Japan) ........................................................................................................ 4513


Clinical Studies

* Review: Estrogen Pathway Polymorphisms and Mammographic Density. I. DUMAS, C. DIORIO (Quebec City, QC, Canada) ..............................................................................................................................

* Review: Targeting AKT Protein Kinase in Gastric Cancer. K. ALMHANNA, J. STROSBERG, M. MALAFA (Tampa, FL, USA) ..............................................................................................................................

Feasibility of Image-guided Radiotherapy Based on Tomotherapy for the Treatment of Locally Advanced Anal Carcinoma. N.P. NGUYEN, J. VOCK, T. SROKA, R. KHAN, S. JANG, A. CHI, M. BETZ, L. EWELL, D. COHEN, R.P. VO, M. MILLS, V. VINH-HUNG (Galveston, TX, USA; Bern; Geneva, Switzerland) ....

Primary Peritoneal Carcinoma in Complete Remission: a Case Report. J. RAMOS, K.S. GUNTURU, S. KRISHNAMOORTHY, B. KENNEY, M.W. SAIF (New Haven, CT; New York, NY, USA) ....................................................................................


Triple Induction Chemotherapy and Chemoradiotherapy for Locally Advanced Esophageal Cancer. A Phase II Study. W. EISTERER, A. DE VRIES, D. KENDLER, B. SPECHTENHAUSER, A. KÖNIGSRAINER, H. NEHODA, I. VIRGOLINI, P. LUKAS, O. BECHTER, E. WÖLL, D. ÖFNER (Innsbruck; Feldkirch; Kufstein; St. Johann; Zams; Salzburg, Austria; Tübingen, Germany) ..............................................................................................................................


Impaired Bone Microenvironment: Correlation between Bone Density and Presence of Disseminated Tumor Cells. B. KRAEMER, R. ROTHMUND, M. BANYS, N. KRAWCZYK, E.-F. SOLOMAYER, C. MACK, D. WALLWIENER, T. FEHM (Tuebingen; Hamburg; Homburg, Germany) ..............................................................................................................................

Contents continued on the preceding page


Resveratrol Reduces TNF-α-induced U373MG Human Glioma Cell Invasion through Regulating NF-κB Activation and uPA/uPAR Expression. J. RYU, B.M. KU, Y.K. LEE, J.Y. JEONG, S. KANG, J. CHOI, Y. YANG, D.H. LEE, G.S. ROH, H.J. KIM, G.J. CHO, W.S. CHOI, N. KIM, S.S. KANG (Jinju; Gimhae; Seoul, South Korea) .................................................. 4223

Quantitative Structure-Activity Relationship (QSAR) Analysis of Tumor-specificity of 1,2,3,4-Tetrahydroisoquinoline Derivatives. Y. UESAWA, K. MOHRI, M. KAWASE, M. ISHIHARA, H. SAKAGAMI (Tokyo; Matsuyama; Saitama, Japan) .......................................................... 4231


Mutations of Mitochondrial DNA as Potential Biomarkers in Breast Cancer. F.F. CAI, C. KOHLER, B. ZHANG, W.J. CHEN, Z. BAREKATI, H.S.P. GARRITSEN, P. LENNER, P. TONIOLO, J.J. ZHANG, X.Y. ZHONG (Basel; Lausanne, Switzerland; Braunschweig, Germany; Umeå, Sweden; Hefei, PR China) .................................................. 4267

Differential CD133 Expression Pattern during Mouse Colon Tumorigenesis. V. ARENA, E. CAREDDA, V. CIFUNO, E. STIGLIANO, F. SCALDAFERRI, A. GASBARRINI, A. CITTADINI, A. SGAMBATO (Rome, Italy) .................................................. 4273

The Expression of Ki-67, but Not Proliferating Cell Nuclear Antigen, Predicts Poor Disease Free Survival in Patients with Adenocarcinoma of the Lung. S. OKA, H. URAMOTO, H. SHIMOKAWA, T. IWANAMI, F. TANAKA (Kitakyushu, Japan) .................................................. 4277

Synergism from the Combination of Oxaliplatin with Selected Phytochemicals in Human Ovarian Cancer Cell Lines. N.M. YUNOS, P. BEALE, J.Q. YU, F. HUQ (Kepong, Malaysia; Sydney, NSW, Australia) .................................................. 4283


Characterization of T-Cell Memory Phenotype after In Vitro Expansion of Tumor-infiltrating Lymphocytes from Melanoma Patients. J. ZHOU, P. NAGARKATTI, Y. ZHONG, M. NAGARKATTI (Columbia, SC, USA) ...... 4099

Effects of Artemisinin Dimers on Rat Breast Cancer Cells In Vitro and In Vivo. N.P. SINGH, H.C. LAI, J.S. PARK, T.E. GERHARDT, B.J. KIM, S. WANG, T. SASAKI (Seattle, WA, USA) ........................................... 4111

Histone-modifier Gene Expression Profiles Are Associated with Pathological and Clinical Outcomes in Human Breast Cancer. N. PATANI, W.G. JIANG, R.F. NEWBOLD, K. MOKBEL (London; Cardiff, Wales, UK) .... 4115

PINCH mRNA Overexpression in Colorectal Carcinomas Correlated with VEGF and FAS mRNA Expression. Z.Y. ZHANG, Y.F. TIAN, Y.Y. WANG, L.J. ZHANG, Z.R. ZHAO, X.F. SUN (Tangshan; Shijiazhuang, PR China; Linköping, Sweden) .......................................................... 4127

ERCC1 Expression and Outcomes in Head and Neck Cancer Treated with Concurrent Cisplatin and Radiation. M. HAYES, C. LAN, J. YAN, Y. XIE, T. GRAY, R.H. AMIRKHAN, J.E. DOWELL (Miramar Beach, FL; Modesto, CA; Dallas, TX, USA) ................................................................................................. 4135

Treatment of Bone Metastasis in Prostate Cancer: Efficacy of a Novel Polybisphosphonate. F. DAUBINE, R. LE BOT, M. MÁRQUEZ, S. NILSSON, T. SCHRÖDER, A.R. HOLMBERG (Nantes, France; Stockholm, Sweden) .......................................................................................................................... 4141

REG4, NEIL2, and BIRC5 Gene Expression Correlates with Gamma-radiation Sensitivity in Patients with Rectal Cancer Receiving Radiotherapy. T. KOBUNAI, T. WATANABE, T. FUKUSATO (Tokyo, Japan) .... 4147

Overexpressed HER2 in NSCLC Is a Possible Therapeutic Target of EGFR Inhibitors. N. ISE, K. OMI, D. NAMBARA, S. HIGASHIYAMA, K. GOISHI (Tokyo; Ehime, Japan) .......................................................... 4155

Acridine Orange Inhibits Pulmonary Metastasis of Mouse Osteosarcoma. H. SATONAKA, K. KUSUZAKI, K. AKEDA, M. TSUJII, T. INO, T. UEMURA, T. MATSUBARA, T. NAKAMURA, K. ASANUMA, A. MATSUMINE, A. SUDO (Tsu City, Mie; Kyoto City, Kyoto, Japan) .......................................................... 4163

Effects of Inorganic and Organic Arsenic Compounds on Growth and Apoptosis of Human T-Lymphoblastoid Leukemia Cells. E. HIKITA, M. ARAI, S. TANAKA, K. ONDA, H. UTSUMI, B. YUAN, H. TOYODA, T. HIRANO (Hachioji; Tokyo, Tokyo; Sagamihara, Kanagawa, Japan) .......................................................................................................................... 4169

Mutational Screening of RET, HRAS, NRAS, BRAF, AKT1, and CTNNB1 in Medullary Thyroid Carcinoma. H.-J. SCHULTEN, J. AL-MAGHRABI, K. AL-GHAMDI, S. SALAMA, S. AL-MUHAYAWI, A. CHAUDHARY, O. HAMOUR, A. ABUZENADAH, M. GARI, M. AL-QAHTANI (Jeddah, Saudi Arabia) .... 4179

Inactivated Orf virus (Parapoxvirus ovis) Induces Antitumoral Activity in Transplantable Tumor Models. H.-H. FIEBIG, A. SIEGLING, H.-D. VOLK, A. FRIEBE, P. KNOLLE, A. LIMMER, O. WEBER (Freiburg; Wuppertal; Bonn, Germany) .......................................................... 4185

Expression of the Apoptosis-related Genes Bcl-2 and p53 in Clinical Samples from Endometrial Carcinoma Patients. I. GONZÁLEZ-RODILLA, V. VERNA, A.-B. MUÑOZ, J. ESTÉVEZ, M. BOIX, J. SCHNEIDER (Santander, Spain) .......................................................... 4191

Yeast-derived Beta-(1-3),(1-6)-D-glucan Induces Up-regulation of CD86 on Dectin-1-positive Human B-Lymphoma Cell Lines. U. HARNACK, U. KELLERMANN, G. PECHER (Berlin, Germany) .......................................................... 4195

Thioridazine Induces Apoptosis of Multidrug-resistant Mouse Lymphoma Cells Transfected with the Human ABCB1 and Inhibits the Expression of P-Glycoprotein. G. SPENGLER, J. MOLNAR, M. VIVEIROS, L. AMARAL (Szeged, Hungary; Lisboa, Portugal; Brussels, Belgium) .......................................................... 4201

Reliability of Direct Sequencing of EGFR: Comparison between Cytological and Histological Samples from the Same Patient. P. BRUNO, S. MARIOTTA, A. RICCI, E. DURANTI, D. SCOZZI, A. NOTO, R. MANCINI, E. GIARNIERI, M.R. GIOVAGNOLI (Rome, Italy) .......................................................... 4207

Contents continued on the preceding page